IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 22.83

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.28 (+0.20%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.19 (+0.29%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.42 (+0.40%)

USD 1.09B
XHE SPDR® S&P Health Care Equipme..

+0.72 (+0.80%)

USD 0.21B
SBIO ALPS Medical Breakthroughs ETF

+0.64 (+1.90%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.68 (+0.75%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.16 (+0.55%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.69 (+1.13%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.42 (+1.71%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

+0.19 (+0.39%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.78% 10% F 35% F
Dividend Return 0.48% 38% F 5% F
Total Return -0.30% 10% F 25% F
Trailing 12 Months  
Capital Gain -1.59% 10% F 33% F
Dividend Return 0.48% 38% F 5% F
Total Return -1.12% 14% F 25% F
Trailing 5 Years  
Capital Gain -24.23% 10% F 23% F
Dividend Return 3.04% 53% F 8% B-
Total Return -21.19% 10% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -3.80% 5% F 16% F
Dividend Return -3.27% 5% F 11% F
Total Return 0.53% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 33.68% 14% F 31% F
Risk Adjusted Return -9.71% 5% F 15% F
Market Capitalization 0.12B 60% D- 30% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.